Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Roivant Sciences Ltd. or GSK plc because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Roivant Sciences Ltd. and GSK plc compare based on key financial metrics to determine which better meets your investment needs.

About Roivant Sciences Ltd. and GSK plc

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves’ disease, difficult-to-treat rheumatoid arthritis, sjögren’s disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company’s lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.

Latest Biotechnology and Roivant Sciences Ltd., GSK plc Stock News

As of September 1, 2026, Roivant Sciences Ltd. had a $24.9 billion market capitalization, compared to the Biotechnology median of $282.5 million. Roivant Sciences Ltd.’s stock is up 57.5% in 2026, down 7% in the previous five trading days and up 189.36% in the past year.

Currently, Roivant Sciences Ltd. does not have a price-earnings ratio. Roivant Sciences Ltd.’s trailing 12-month revenue is $7.5 million with a % net profit margin. Year-over-year quarterly sales growth most recently was -36.4%. Analysts expect adjusted earnings to reach $-1.580 per share for the current fiscal year. Roivant Sciences Ltd. does not currently pay a dividend.

As of September 1, 2026, GSK plc had a $101.3 billion market cap, putting it in the 97th percentile of all stocks. GSK plc’s stock is up 2.9% in 2026, down 1.9% in the previous five trading days and up 27.7% in the past year.

Currently, GSK plc’s price-earnings ratio is 32.4. GSK plc’s trailing 12-month revenue is $44.1 billion with a 14.5% net profit margin. Year-over-year quarterly sales growth most recently was 2.0%. Analysts expect adjusted earnings to reach $4.794 per share for the current fiscal year. GSK plc currently has a 3.6% dividend yield.

How We Compare Roivant Sciences Ltd. and GSK plc Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Roivant Sciences Ltd. and GSK plc’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Roivant Sciences Ltd. and GSK plc Stock Value Grades

Company	Ticker	Value
Roivant Sciences Ltd.	ROIV	na
GSK plc	GSK	D

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Roivant Sciences Ltd. does not have a meaningful Value Score. GSK plc has a Value Score of 31, which is Expensive.

The Value Stock Winner: No Clear Winner

Neither Roivant Sciences Ltd. or GSK plc has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Roivant Sciences Ltd. or GSK plc is the better investment when it comes to value.

Roivant Sciences Ltd. and GSK plc Growth Grades

Company	Ticker	Growth
Roivant Sciences Ltd.	ROIV	F
GSK plc	GSK	A

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Roivant Sciences Ltd. has a Growth Score of 3, which is Very Weak. GSK plc has a Growth Score of 83, which is Very Strong.

The Growth Grade Winner: GSK plc

As you can clearly see from the Growth Grade breakdown above, GSK plc has a more attractive growth grade than Roivant Sciences Ltd.. For investors who focus solely on how a company is growing relative to other companies in the same industry, GSK plc could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Roivant Sciences Ltd. and GSK plc’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Roivant Sciences Ltd.	ROIV	D
GSK plc	GSK	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Roivant Sciences Ltd. has a Earnings Estimate Score of 28, which is Negative. GSK plc has a Earnings Estimate Score of 69, which is Positive.

The Earnings Estimate Revisions Grade Winner: GSK plc

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, GSK plc has a better Earnings Estimate Revisions Grade than Roivant Sciences Ltd.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, GSK plc could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Roivant Sciences Ltd. and GSK plc Grades

In addition to Estimate Revisions, Value and Growth, A+ Investor also provides grades for Momentum and Quality.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Roivant Sciences Ltd. and GSK plc pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Roivant Sciences Ltd. or GSK plc Stock?

Overall, Roivant Sciences Ltd. stock has a Value Score of , Growth Score of 3 and Estimate Revisions Score of 28.

GSK plc stock has a Value Score of 31, Growth Score of 83 and Estimate Revisions Score of 69.

Comparing Roivant Sciences Ltd. and GSK plc’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.